| Year |
Citation |
Score |
| 2005 |
Laxmikanthan G, Blaber SI, Bernett MJ, Scarisbrick IA, Juliano MA, Blaber M. 1.70 A X-ray structure of human apo kallikrein 1: structural changes upon peptide inhibitor/substrate binding. Proteins. 58: 802-14. PMID 15651049 DOI: 10.1002/Prot.20368 |
0.409 |
|
| 2004 |
Bernett MJ, Somasundaram T, Blaber M. An atomic resolution structure for human fibroblast growth factor 1. Proteins. 57: 626-34. PMID 15382229 DOI: 10.1002/Prot.20239 |
0.524 |
|
| 2004 |
Blaber SI, Ciric B, Christophi GP, Bernett MJ, Blaber M, Rodriguez M, Scarisbrick IA. Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 18: 920-2. PMID 15033932 DOI: 10.1096/Fj.03-1212Fje |
0.577 |
|
| 2002 |
Bernett MJ, Blaber SI, Scarisbrick IA, Dhanarajan P, Thompson SM, Blaber M. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. The Journal of Biological Chemistry. 277: 24562-70. PMID 11983703 DOI: 10.1074/Jbc.M202392200 |
0.639 |
|
| 2002 |
Blaber SI, Scarisbrick IA, Bernett MJ, Dhanarajan P, Seavy MA, Jin Y, Schwartz MA, Rodriguez M, Blaber M. Enzymatic properties of rat myelencephalon-specific protease. Biochemistry. 41: 1165-73. PMID 11802715 DOI: 10.1021/Bi015781A |
0.593 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2010 |
Bernett MJ, Karki S, Moore GL, Leung IW, Chen H, Pong E, Nguyen DH, Jacinto J, Zalevsky J, Muchhal US, Desjarlais JR, Lazar GA. Engineering fully human monoclonal antibodies from murine variable regions. Journal of Molecular Biology. 396: 1474-90. PMID 20045416 DOI: 10.1016/j.jmb.2009.12.046 |
0.227 |
|
| 2012 |
Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S, Bernett MJ, Nguyen DH, Karki S, Chu SY, Lazar GA, Munshi NC, Desjarlais JR, Anderson KC, Muchhal US. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 119: 2074-82. PMID 22246035 DOI: 10.1182/blood-2011-06-364521 |
0.188 |
|
| 2008 |
Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Research. 68: 8049-57. PMID 18829563 DOI: 10.1158/0008-5472.CAN-08-2268 |
0.164 |
|
| 2013 |
Bernett MJ, Chu SY, Leung I, Moore GL, Lee SH, Pong E, Chen H, Phung S, Muchhal US, Horton HM, Lazar GA, Desjarlais JR, Szymkowski DE. Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn. Mabs. 5: 384-96. PMID 23549103 DOI: 10.4161/mabs.23976 |
0.149 |
|
| 2021 |
Atyeo C, Slein MD, Fischinger S, Burke J, Schäfer A, Leist SR, Kuzmina NA, Mire C, Honko A, Johnson R, Storm N, Bernett M, Tong P, Zuo T, Lin J, et al. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. Jci Insight. 6. PMID 33427208 DOI: 10.1172/jci.insight.143129 |
0.143 |
|
| 2000 |
Bernett MJ, Tipton AK, Huggins MT, Reeder JH, Lightner DA. Supramolecular ribbons. Crystal structure and spectroscopic properties of 2,2′-bipyrroyl Monatshefte Fur Chemie. 131: 239-249. DOI: 10.1007/Pl00010308 |
0.141 |
|
| 2023 |
Nolan-Stevaux O, Li C, Liang L, Zhan J, Estrada J, Osgood T, Li F, Zhang H, Case R, Murawsky CM, Estes B, Moore GL, Bernett MJ, Muchhal U, Desjarlais JR, et al. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity Against Prostate Cancer. Cancer Discovery. PMID 37861452 DOI: 10.1158/2159-8290.CD-23-0984 |
0.135 |
|
| 2010 |
Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY, Richards JO, Chen H, Repp R, Desjarlais JR, Zhukovsky EA. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood. 116: 3004-12. PMID 20616215 DOI: 10.1182/blood-2010-01-265280 |
0.129 |
|
| 2018 |
Moore GL, Bernett MJ, Rashid R, Pong EW, Nguyen DT, Jacinto J, Eivazi A, Nisthal A, Diaz JE, Chu SY, Muchhal US, Desjarlais JR. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats. Methods (San Diego, Calif.). PMID 30366098 DOI: 10.1016/j.ymeth.2018.10.006 |
0.107 |
|
| 2023 |
Lu D, Yadav R, Holder P, Chiang E, Sanjabi S, Poon V, Bernett M, Varma R, Liu K, Leung I, Bogaert L, Desjarlais J, Shivva V, Hosseini I, Ramanujan S. Complex PK-PD of an engineered IL-15/IL-15Rα-Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 106450. PMID 37084985 DOI: 10.1016/j.ejps.2023.106450 |
0.097 |
|
| 2012 |
Chu SY, Horton HM, Pong E, Leung IW, Chen H, Nguyen DH, Bautista C, Muchhal US, Bernett MJ, Moore GL, Szymkowski DE, Desjarlais JR. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody. The Journal of Allergy and Clinical Immunology. 129: 1102-15. PMID 22257644 DOI: 10.1016/j.jaci.2011.11.029 |
0.083 |
|
| 2019 |
Zuch de Zafra CL, Fajardo F, Zhong W, Bernett MJ, Muchhal US, Moore GL, Stevens J, Case R, Pearson JT, Liu S, McElroy P, Canon J, Desjarlais J, Desjarlais J, Coxon A, et al. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T Cell-Recruiting Antibody Optimized for Cytotoxicity and Cytokine Release. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30918018 DOI: 10.1158/1078-0432.Ccr-18-2752 |
0.07 |
|
| Hide low-probability matches. |